ArticleKidney international reports2026
Potential Benefit of Sodium-Glucose Cotransporter 2-Inhibitors in Cisplatin-Associated Nephrotoxicity Among Patients With Cancer Having Diabetes Mellitus.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cisplatin is often nephrotoxic, frequently causing treatment interruptions or discontinuation. Mitigation includes dose adjustments, hydration, and supplemental magnesium. Sodium-glucose cotransporter-2 inhibitors (SGLT2is) may protect the kidneys by reducing tubular cells' cisplatin uptake. We examined the potential kidney protective effect of SGLT2i in patients with cancer having diabetes mellitus receiving cisplatin. Methods: We conducted a single-center retrospective study of patients who received i.v. cisplatin from July 2017 to January 2024. Data extracted included comorbidities, variables associated with acute kidney injury (AKI; defined as ≥ 50% serum creatinine increase within 4 weeks), hyponatremia, hypomagnesemia, and anemia. Patients were divided according to SGLT2i exposure at cisplatin initiation and matched 1:1 using inverse propensity scores based on baseline characteristics. Descriptive statistics summarized baseline and outcome variables; parametric or nonparametric tests assessed group differences. Logistic regression and analysis of variance were used for further outcome analyses. Results: A total of 288 patients ( Conclusion: Our findings suggest that continuation of SGLT2i may offer kidney-protective effects against AKI in patients with diabetes mellitus undergoing cisplatin chemotherapy. A well-designed randomized clinical trial is needed to validate this potential benefit.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.